Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma

Şahin, Asena Keleş; Uzun, Aslıhan

doi:10.18240/ijo.2022.03.17

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to niacin, citicoline protection against RGC damage has been extensively demonstrated in different models of RGC injury ( 20 , 21 ). At the clinical level, citicoline administration to glaucoma patients appears to slow down glaucoma progression by exerting neuroprotective effects ( 22 , 23 ). Preclinical and clinical data on the efficacy of citicoline supplementation in glaucoma have been comprehensively reviewed by Grieb et al ( 24 ).…”

Section: Introductionmentioning

confidence: 99%

Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma

Melecchi,

Amato,

Dal Monte

et al. 2023

Front. Med.

View full text Add to dashboard Cite

IntroductionMuch interest has been addressed to antioxidant dietary supplements that are known to lower the risk of developing glaucoma or delay its progression. Among them, niacin and citicoline protect retinal ganglion cells (RGCs) from degeneration by targeting mitochondria, though at different levels. A well-established mouse model of RGC degeneration induced by experimental intraocular pressure (IOP) elevation was used to investigate whether a novel combination of niacin/citicoline has better efficacy over each single component in preserving RGC health in response to IOP increase.MethodsOcular hypertension was induced by an intracameral injection of methylcellulose that clogs the trabecular meshwork. Electroretinography and immunohistochemistry were used to evaluate RGC function and density. Oxidative, inflammatory and apoptotic markers were evaluated by Western blot analysis.ResultsThe present results support an optimal efficacy of niacin with citicoline at their best dosage in preventing RGC loss. In fact, about 50% of RGCs were spared from death leading to improved electroretinographic responses to flash and pattern stimulation. Upregulated levels of oxidative stress and inflammatory markers were also consistently reduced by almost 50% after niacin with citicoline thus providing a significant strength to the validity of their combination.ConclusionNiacin combined with citicoline is highly effective in restoring RGC physiology but its therapeutic potential needs to be further explored. In fact, the translation of the present compound to humans is limited by several factors including the mouse modeling, the higher doses of the supplements that are necessary to demonstrate their efficacy over a short follow up period and the scarce knowledge of their transport to the bloodstream and to the eventual target tissues in the eye.

show abstract

Section: Introductionmentioning

confidence: 99%

Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma

Melecchi,

Amato,

Dal Monte

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Oral citicoline has been reported to increase the release of dopamine and norepinephrine and its efficacy has been proved in several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, as well as in ischemic and traumatic brain injury. The possible neuro-enhancing effect, possibly due to the dopamine increase, justifies the improvement of visual field and electrophysiological test results obtained in glaucomatous patients ( 46 , 47 ).…”

Section: Citicolinementioning

confidence: 77%

“…Evidence of its ability to reduce glutamate-mediated excitotoxicity and oxidative stress by boosting neurotrophin levels and supporting mitochondrial activity endorsed the use of citicoline in neurodegenerative diseases ( 47 ).…”

Section: Citicolinementioning

confidence: 99%

See 1 more Smart Citation

Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma

et al. 2022

View full text Add to dashboard Cite

Glaucoma is the leading cause of irreversible blindness worldwide. Several risk factors have been involved in the pathogenesis of the disease. By now, the main treatable risk factor is elevated intraocular pressure. Nevertheless, some patients, whose intraocular pressure is considered in the target level, still experience a progression of the disease. Glaucoma is a form of multifactorial ocular neurodegeneration with complex etiology, pathogenesis, and pathology. New evidence strongly suggests brain involvement in all aspects of this disease. This hypothesis and the need to prevent glaucomatous progression led to a growing interest in the pharmacological research of new neuroprotective, non-IOP-lowering, agents. The aim of this paper is to report evidence of the usefulness of Coenzyme Q10 and Citicoline, eventually combined, in the prevention of glaucomatous neurodegeneration.

show abstract

“…Hasil penelitian ini menunjukkan terapi citicoline oral efektif mencegah perburukan glaukoma sudut terbuka. 13 Studi Sahin AK, et al, 14 menunjukkan rerata ketebalan RNFL lebih tinggi bermakna (p=0,038) pada bulan ketiga dibandingkan awal pada kelompok citicoline oral 250 mg. Perbaikan ini mengalami regresi parsial setelah periode wash out satu bulan. Tidak terdapat perubahan bermakna pada RNFL kuadran superior, nasal, temporal, dan inferior pada bulan ketiga dan keempat (p>0,05).…”

Section: Dapat Digunakan Untuk Memberikan Kombinasi Obat Dengan Dosis...unclassified

Peran Citicoline Oral Sebagai Terapi Tambahan dalam Pengobatan Glaukoma

Sinaga

2024

Cermin Dunia Kedokteran

View full text Add to dashboard Cite

Glaucoma is the second-leading global cause of blindness. Lowering intraocular pressure can prevent the worsening of open-angle glaucoma, but alternative neuroprotective therapies are needed; citicoline is supposed to have neuroprotective potential. This evidence-based case report was to review the effectiveness of oral citicoline as an adjunct therapy for glaucoma. From 22 studies identified through PubMed, Scopus, Cochrane, EBSCO Host, and Google Scholar, three articles were selected for critical review. Lanza M. found the RNFL and GCC of the citicoline group 500 mg were significantly higher, 70.39 and 71.19 Pm, p<0,01 compared to controls, after 12 months. Sahin A, et al, showed that the RNFL was significantly higher in the third month than baseline in the oral citicoline 250 mg group, p = 0.038. Putri VC, et al, found that after 60 days, based on sub-group analysis, there was a significant difference in RNFL and GCIPL thickness changes after citicoline 500 mg intervention in the mild glaucoma group and after citicoline 1,000 mg in the moderate-severe glaucoma group. Oral citicoline supplementation prevents significant worsening of glaucoma, it can be given as an adjunct therapy.

show abstract

Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma

Cited by 9 publications

References 29 publications

Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma

Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma

Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma

Peran Citicoline Oral Sebagai Terapi Tambahan dalam Pengobatan Glaukoma

Contact Info

Product

Resources

About